Of these, 84 patients had a TNBC (14.7%), 212 patients (37.1%) had Luminal A-like, 206 patients (36.0%) had Luminal B-like and 70 patients (12.2%) had HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.